DHDaniel Habermehl

Daniel Habermehl

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daniel Habermehl has a total of 102 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long term results after fractionated stereotactic radiotherapy (FSRT) in patients with craniopharyngioma: maximal tumor control with minimal side effects

    by Semi B Harrabi, Sebastian Adeberg, Thomas Welzel, Stefan Rieken, Daniel Habermehl, Jürgen Debus, Stephanie E Combs

    There are already numerous reports about high local control rates in patients with craniopharyngioma but there are only few studies with follow up times of more than 10 years. This study is an analysis of long term control, tumor response and side effects after fractionated stereotactic radiotherapy (FSRT) for patients with craniopharyngioma. 55 patients who were treated with FSRT for craniopharyngioma were analyzed. Median age was 37 years (range 6–70 years), among them eight children < 18 years. Radiotherapy (RT) was indicated for progressive disease after neurosurgical resection or postoperatively after repeated resection or partial resection. A median dose of 52.2 Gy (50 – 57.6 Gy) was applied with typical dose per fraction of 1.8 Gy five times per week. The regular follow up examinations comprised in addition to contrast enhanced MRI scans thorough physical examinations and clinical evaluation. During median follow up of 128 months (2 – 276 months) local control rate was 95.3% after 5 years, 92.1% after 10 years and 88.1% after 20 years. Overall survival after 10 years was 83.3% and after 20 years 67.8% whereby none of the deaths were directly attributed to craniopharyngioma. Overall treatment was tolerated well with almost no severe acute or chronic side effects. One patient developed complete anosmia, another one’s initially impaired vision deteriorated further. In 83.6% of the cases with radiological follow up a regression of irradiated tumor residues was monitored, in 7 cases complete response was achieved. 44 patients presented themselves initially with endocrinologic dysfunction none of them showed signs of further deterioration during follow up. No secondary malignancies were observed. Long term results for patients with craniopharyngioma after stereotactic radiotherapy are with respect to low treatment related side effects as well as to local control and overall survival excellent.


  • Open Access

    Spinal bone metastases in gynecologic malignancies: a retrospective analysis of stability, prognostic factors and survival

    by Robert Foerster, Daniel Habermehl, Thomas Bruckner, Tilman Bostel, Ingmar Schlampp, Thomas Welzel, Juergen Debus, Harald Rief

    The aim of this retrospective study was to evaluate the stability of spinal metastases in gynecologic cancer patients (pts) on the basis of a validated scoring system after radiotherapy (RT), to define prognostic factors for stability and to calculate survival. Fourty-four women with gynecologic malignancies and spinal bone metastases were treated at our department between January 2000 and January 2012. Out of those 34 were assessed regarding stability using the Taneichi score before, 3 and 6 months after RT. Additionally prognostic factors for stability, overall survival, and bone survival (time between first day of RT of bone metastases and death from any cause) were calculated. Before RT 47% of pts were unstable and 6 months after RT 85% of pts were stable. Karnofsky performance status (KPS) >70% (p = 0.037) and no chemotherapy (ChT) (p = 0.046) prior to RT were significantly predictive for response. 5-year overall survival was 69% and 1-year bone survival was 73%. RT is capable of improving stability of osteolytic spinal metastases from gynecologic cancer by facilitating re-ossification in survivors. KPS may be a predictor for response. Pts who received ChT prior to RT may require additional bone supportive treatment to overcome bone remodeling imbalance. Survival in women with bone metastases from gynecologic cancer remains poor.


  • Radiotherapy in patients with vestibular schwannoma and neurofibromatosis type 2: clinical results and review of the literature

    by Johanna Wagner, Thomas Welzel, Daniel Habermehl, Jürgen Debus, Stephanie E Combs

    To evaluate the long-term outcome of patients with vestibular schwannoma (VS) and neurofibromatosis type 2 (NF2) treated with fractionated stereotactic radiotherapy (FSRT) or stereotactic radiosurgery (SRS). Sixteen VS in 14 patients with NF2 were treated with FSRT (n = 14) and SRS (n = 2). Patients with tumor progression and/or progression of clinical symptoms were selected for treatment. For patients treated with FSRT a median total dose of 57.6 Gy was prescribed with a median fractionation of 5 × 1.8 Gy per week. For patients who underwent SRS a median single dose of 17 Gy was prescribed to the 80% isodose. FSRT and SRS were well tolerated. Local control rate was 94% for a median follow-up time of 131 months; 2- and 5-year progression-free survival were 100%. The probability of maintaining the pretreatment hearing level was 44%. Useful hearing preservation was 33%. Cranial nerve toxicity was moderate. Trigeminal nerve function worsened in 2 patients (12%) and facial nerve function in 3 patients (19%). One patient developed a new tinnitus. FSRT and SRS are both safe and effective noninvasive and minimally invasive treatment options for patients with VS in the setting of NF2. The long-term local control rates are excellent. Functional hearing preservation is worse in patients with VS and NF2 than in patients with sporadic VS.


  • Open Access

    Stability of spinal bone metastases in breast cancer after radiotherapy

    by Ingmar Schlampp, Stefan Rieken, Daniel Habermehl, Thomas Bruckner, Robert Förster, Jürgen Debus, Harald Rief

    This retrospective analysis was performed to evaluate osteolytic bone lesions of breast cancer in the thoracic and lumbar spine after radiotherapy (RT) in terms of stability using a validated scoring system.


  • Photon-induced cell migration and integrin expression promoted by DNA integration of HPV16 genome

    by Stefan Rieken, Florian Simon, Daniel Habermehl, Jan Oliver Dittmar, Stephanie E. Combs, Klaus Weber, Jürgen Debus, Katja Lindel

    Persistent human papilloma virus 16 (HPV16) infections are a major cause of cervical cancer. The integration of the viral DNA into the host genome causes E2 gene disruption which prevents apoptosis and increases host cell motility. In cervical cancer patients, survival is limited by local infiltration and systemic dissemination. Surgical control rates are poor in cases of parametrial infiltration. In these patients, radiotherapy (RT) is administered to enhance local control. However, photon irradiation itself has been reported to increase cell motility. In cases of E2-disrupted cervical cancers, this phenomon would impose an additional risk of enhanced tumor cell motility. Here, we analyze mechanisms underlying photon-increased migration in keratinocytes with differential E2 gene status. Isogenic W12 (intact E2 gene status) and S12 (disrupted E2 gene status) keratinocytes were analyzed in fibronectin-based and serum-stimulated migration experiments following single photon doses of 0, 2, and 10 Gy. Quantitative FACS analyses of integrin expression were performed. Migration and adhesion are increased in E2 gene-disrupted keratinocytes. E2 gene disruption promotes attractability by serum components, therefore, effectuating the risk of local infiltration and systemic dissemination. In S12 cells, migration is further increased by photon RT which leads to enhanced expression of fibronectin receptor integrins. HPV16-associated E2 gene disruption is a main predictor of treatment-refractory cancer virulence. E2 gene disruption promotes cell motility. Following photon RT, E2-disrupted tumors bear the risk of integrin-related infiltration and dissemination. Persistierende Infektionen mit humanen Papillomaviren 16 (HPV16) sind ein Hauptauslöser des Zervixkarzinoms. Die Integration der viralen DNS in das Wirtszellgenom führt zum Integritätsverlust des E2-Gens, wodurch in der Wirtszelle Apoptose verhindert und Motilität gesteigert werden. In Zervixkarzinompatientinnen bestimmen die lokale Infiltration und die systemische Metastasierung die Überlebensraten. Bei parametraner Infiltration sind die Kontrollraten der Chirurgie schlecht, so dass die Photonenbestrahlung zur Steigerung der lokalen Kontrolle eingesetzt wird. Photonenbestrahlungen selbst sind jedoch als motilitätsfördernd beschrieben worden, so dass im Fall eines HPV16-integrierten Zervixkarzinoms diese Therapie ein zusätzliches Risiko der Förderung von Migration und Infiltration birgt. In der vorliegenden Arbeit untersuchen wir den Einfluss der genomischen HPV16-Integration auf die radiogene Modifizierbarkeit der Migration dysplastischer Keratinozyten. Isogene HPV16-infizierte Keratinozyten mit entweder intaktem (W12-) oder aber defizientem E2-Genstatus (S12) wurden in Fibronektin-basierten und serumstimulierten Migrationsexperimenten nach Photonenbestrahlung mit Einzeldosen von 0, 2 und 10,0 Gy analysiert. Im Anschluss erfolgten quantitative FACS-Bestimmungen der Integrinexpression. Sowohl Migration als auch Adhäsion sind in E2-defizienten Keratinozyten gesteigert. In diesen Zellen zeigt sich eine signifikante Stimulierbarkeit der Migration durch Serumbestandteile. Ferner exprimieren diese Zellen nach Photonenbestrahlung signifikant mehr Fibronektin-bindende Integrine, wodurch ihr Migrationsvermögen radiogen deutlich gesteigert wird. Der durch die Integration von HPV16 verursachte Verlust des E2-Gens stellt eine Ursache radioresistenter Tumorvirulenz dar. E2-defiziente Zellen sind nicht nur hypermotil und durch Serumbestandteile lockbar, sondern zeigen nach Photonenbestrahlung eine gesteigerte Integrinexpression, welche das Risiko für Infiltration und Metastasierung zusätzlich begünstigt.


  • Open Access

    Feasibility of isometric spinal muscle training in patients with bone metastases under radiation therapy - first results of a randomized pilot trial

    by Harald Rief, Georg Omlor, Michael Akbar, Thomas Welzel, Thomas Bruckner, Stefan Rieken, Matthias F Haefner, Ingmar Schlampp, Alexandros Gioules, Daniel Habermehl, et al.

    Spinal bone metastases are commonly diagnosed in cancer patients. The consequences are pain both at rest and under exercise, impairment of activities of daily life (ADL), reduced clinical performance, the risk of pathological fractures, and neurological deficits. The aim of this randomized, controlled pilot trial was to investigate the feasibility of muscle-training exercises in patients with spinal bone metastases under radiotherapy. Secondary endpoints were local control, pain response and survival.


  • Open Access

    Phase I study evaluating the treatment of patients with locally advanced pancreatic cancer with carbon ion radiotherapy: the PHOENIX-01 trial

    by Stephanie E Combs, Daniel Habermehl, Meinhard Kieser, Constantin Dreher, Jens Werner, Renate Haselmann, Oliver Jäkel, Dirk Jäger, Markus W Büchler, Jürgen Debus

    Treatment options for patients with locally advanced pancreatic cancer include surgery, chemotherapy as well as radiotherapy. In many cases, surgical resection is not possible, and therefore treatment alternatives have to be performed. Chemoradiation has been established as a convincing treatment alternative for locally advanced pancreatic cancer. Carbon ions offer physical and biological characteristics. Due to their inverted dose profile and the high local dose deposition within the Bragg peak precise dose application and sparing of normal tissue is possible. Moreover, in comparison to photons, carbon ions offer an increased relative biological effectiveness (RBE), which can be calculated between 1.16 and 2.46 depending on the pancreatic cancer cell line as well as the endpoint analyzed. Japanese Data on the evaluation of carbon ion radiation therapy showed promising results for patients with pancreatic cancer. The present PHOENIX-01 trial evaluates carbon ion radiotherapy using the active rasterscanning technique in patients with advanced pancreatic cancer in combination with weekly gemcitabine and adjuvant gemcitabine. Primary endpoint is toxicity, secondary endpoints are overall survival, progression-free survival and response. The physical and biological properties of the carbon ion beam promise to improve the therapeutic ratio in patients with pancreatic cancer: Due to the inverted dose profile dose deposition in the entry channel of the beam leads to sparing of normal tissue; the Bragg peak can be directed into the defined target volume, and the sharp dose fall-off thereafter again spares normal tissue behind the target volume. The higher RBE of carbon ions, which has been shown also for pancreatic cancer cell lines in the preclinical setting, is likely to contribute to an increase in local control, and perhaps in OS. Early data from Japanese centers have shown promising results. In conclusion, this is the first trial to evaluate actively delivered carbon ion beams in patients with locally advanced pancreatic cancer within a dose-escalation strategy. NCT01795274


  • Open Access

    Single-dose radiosurgical treatment for hepatic metastases - therapeutic outcome of 138 treated lesions from a single institution

    by Daniel Habermehl, Klaus K Herfarth, Justo Lorenzo Bermejo, Holger Hof, Stefan Rieken, Sabine Kuhn, Thomas Welzel, Jürgen Debus, Stephanie E Combs

    Local ablative therapies such as stereotactically guided single-dose radiotherapy or helical intensity-modulated radiotherapy (tomotherapy) with high single-doses are successfully applied in many centers in patients with liver metastasis not suitable for surgical resection. This study presents results from more than 10 years of clinical experience and evaluates long-term outcome and efficacy of this therapeutic approach.